ARTHEx Biotech, aclinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs announced the closing of its €42 million Series B financing round. It has been led by Columbus Venture Partners, with participation of European Innovation Council (EIC), Hadean Ventures, Sound Bioventures, and existing investors Invivo Capital, AdBio Partners, and CDTI. Invivo Capital and AdBio Partners are both members of CataloniaBio & HealthTech, and the first ones participated in the creation of the company and were the first investors. Moreover, they have now played a leading role in attracting Series B investors.

"Invivo Capital is proud to announce an international round of this power, in a company that we created and of which we were the first investors", says Luis Pareras, Founder and Managing Partner of Invivo Capital. "It is a success as a fund dedicated to company creation and early stage investments, in addition to the fact that we have been able to attract investors of the power of Hadean, Sound BioVentures and Columbus Ventures Partners, among others", he adds. 

The Series B proceeds will beused to advance its lead compound, ATX-01 to a Phase I/IIa clinical trial fort he treatment of Myotonic Dystrophy Type 1 (DM1). There are currently no disease-modifying treatments for DM1, which affects at least 40,000 people in the U.S and 70,000 in Europe.